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Summary A phase I study was undertaken in order to establish the maximum tolerated dose of intra-hepatic
arterial 5-fluorouracil (5-FU) when given in combination with systemic folinic acid. Patients with colorectal
liver metastases (n = 10) received escalating doses of 5-FU as a 24 h infusion with a fixed dose (400 mg m-2) of
intravenous folinic acid once per week. Dose limiting toxicity (WHO grade >2) was encountered at 2 g m-2
5-FU. Principal adverse effects were diarrhoea, vomiting and oral ulceration. The recommended dose for phase
II studies is 1.5 gm-2 week-' 24 h 5-FU regional infusion with 400 mg m2 week-' intravenous folinic acid.
The prognosis for patients with colorectal liver metastases
remains depressing; the mean survival in the West of Scot-
land is approximately 3 months (Wood et al., 1976). The
results of systemic chemotherapy have generally been
regarded as disappointing. However, recent randomised trials
have suggested that the addition of folinic acid may
significantly improve survival amongst advanced colorectal
cancer patients receiving intravenous 5-FU (Erlichman, 1988;
Poon et al., 1989; Kerr, 1989). Unfortunately, this advance
has not been without toxicity, which varies according to drug
dose and schedule.
An alternative therapeutic strategy is provided by regional
treatment via a hepatic artery catheter. Higher drug concent-
rations are achieved in the liver with relatively less drug
escaping into the systemic vascular compartment therefore
diminishing systemic toxicity. We have shown in a series of
previous pharmacokinetically guided studies that 24 h intra-
arterial infusion of 5-FU confers a significant phar-
macological advantage relative to intravenous infusions or
intra-arterial bolus administration (Goldberg et al., 1990).
Regional administration of folinic acid is also associated with
a statistically significant reduction in systemic exposure com-
pared with the intravenous route but this apparent phar-
macokinetic advantage has been offset by the potential for
hepatic artery catheter thrombosis with this drug (Anderson
et al., 1991).
For patients with colorectal liver metastases, regional 5-FU
increases response rates compared with intravenous treat-
ment, but there is no convincing evidence that survival is
significantly prolonged (Grage et al., 1979). Disease generally
progresses through development of extra-hepatic metastases.
It would appear, therefore, that many patients with metas-
tatic disease, which is apparently confined to the liver, have
occult micrometastases at other sites.
Clinically, there are two strategies to try to overcome this
problem of systemic relapse following loco-regional therapy:
combination of regional with systemic therapy or dose
escalating the regional therapy until peripheral venous con-
centrations equal those which are achieved with conventional
systemic treatment. We have decided to adopt the latter
approach.
The aim the present study was to establish the maximum
tolerated dose of a 24 h intra-hepatic arterial infusion of
5-FU given in combination with a fixed dose of intravenous
folinic acid. This might allow the generation of high 5-FU
levels within the liver, the site of predominant bulk disease,
whilst maintaining adequate systemic levels.
Patients and methods
Patients
Patients with biopsy-proven, metastatic, colorectal adenocar-
cinoma, confined to the liver were recruited. All subjects had
previously undergone a resection of an adenocarcinoma of
the colon or rectum and surgical placement of a hepatic
artery catheter (Infusaport 38940. Shiley Infusaid Inc., Nor-
wood, MA, USA). The gall-bladder had been removed and
branches of the hepatic artery to extrahepatic organs were
ligated. Following insertion of the catheter, it had been per-
fused with methylene blue to ensure that tissues outwith the
liver were not subjected to the intra-arterial chemotherapy.
Entry criteria were; WHO performance status < 2, life
expectancy >2 months, white cell count >4 x I0' 1'-,
platelets > 150 x 109 1'-l and bilirubin < 30 ymol 1'-. Prior
to commencing treatment, and during each 2-week break
between courses, disease was staged using abdominal CT
scan and chest radiograph. All patients gave informed con-
sent before entering the study.
Treatment
Patients were treated once per week. Each course of therapy
lasted 6 weeks and there was a 2 week break between
courses. 5-FU (25 mg ml-') was delivered percutaneously
into the Infusaport arterial catheter as a continuous 24 h
infusion. The starting dose of 5-FU was 600 mgm-2 week-':
similar to that recommended for intravenous use (Petrelli et
al., 1987). The dose of 5-FU was increased once three
patients had received that dose for at least 3 consecutive
weeks without unacceptable toxicity. Heparin (100 U ml-')
was added to the infusion to reduce the risk of catheter
thrombosis. Folinic acid was administered intravenously at a
fixed total dose of 400 mg m-2 week-'; 200 mg m-2 was
infused over the first 2 h of the 5-FU infusion and the
remaining 200 mg m-2 was infused over the final 2 h of the
5-FU infusion.
Toxicity assessments
Patients were assessed once per week and full blood count,
liver function tests and serum urea and electrolytes were
measured. Toxicity was assessed using standard WHO
criteria on a scale from 0 (absent) to 4 (severe) for each
adverse effect (Miller et al., 1981). Particular attention was
paid to oral ulceration, vomiting, diarrhoea, 'hand foot synd-
rome', alopecia, skin rashes, myelosuppression and serum
bilirubin, AST, ALT, alkaline phosphatase, urea and
creatinine.
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Withdrawalfrom study
The study protocol stated that any patient with disease pro-
gression should be withdrawn from the trial. Dose limiting
toxicity was defined as the dose which produced WHO grade
3 or 4 toxicity.
Results
Patients
Ten patients entered the study (seven males, three females).
Mean age was 58 years (range 47-70). Three patients had
received previous treatment for their metastases (one with
regional radioactive microspheres, one with regional chemo-
therapy followed by systemic monoclonal antibodies and the
third with systemic chemotherapy) but their disease had pro-
gressed despite these measures. No patients had any active
treatment of their metastases within 2 months of entry into
the present trial.
Treatment
The dose of 5-FU was escalated through 0.6, 1, 1.5 and
2 g m-2. The treatment given to each patient is presented in
Table I. Three patients were withdrawn from the study due
to disease progression: patient 4 developed malignant ascites
and patients 3 and 5 had a local recurrence of their primary
tumour. Patient 2 experienced a leak from his injection port
which was complicated by hepatic artery thrombosis thus
rendering further regional therapy impossible.
Toxicity
The toxicity experience in the present study is outlined in
Table II. The only observed adverse effects were vomiting,
diarrhoea and oral ulceration. Patients did not suffer any
clinically significant toxicity (i.e. >WHO grade 1) following
treatment with 0.6 or 1 g m2 5-FU. Only one of the seven
patients who received 1.5 g m2 5-FU had unacceptable side
effects. This patient (patient 7) vomited following each of her
three treatments at this dose. Dose limiting toxicity was
achieved, however, at 2 g m-2 5-FU. Four out of eight
patients treated at this dose experienced intolerable treat-
ment-related symptoms. Of these four patients, the pre-
dominant symptom was vomiting in two (patients 7 and 10)
and diarrhoea in the other two (patients 1 and 6). These
adverse effects lead to dehydration requiring intravenous
fluid replacement in patients 6 and 7. The overall reaction to
2 g m-2 5-FU is shown in Table III. Patients 7 and 10
experienced WHO grade 3/4 toxicity initially after five weeks
of 5-FU 2gmm2 whilst patients 1 and 6 encountered WHO
grade 3/4 toxicity after the 6th week at this dose. On tem-
porary withdrawal of 5-FU all adverse effects resolved in
every patient. Weekly blood count and liver function tests
failed to demonstrate evidence of myelosuppression or
hepatotoxicity in any patient.
Table I Number of weeks at each 5-FU dose for each patient
5-FU Dose (gm-2)
Patient 0.6 1.0 1.5 2.0
1 6 4 8 5
2 6 3 2 4
3 6 0 0 0
4 4 2 0 0
5 0 3 3 1
6 0 0 3 9
7 0 1 3 5
8 0 0 4 9
9 0 0 6 6
10 0 0 6 6
Total 22 13 35 45
Table II Number ofweeks WHO toxicity for each dose of 5-FU
5-FUdose (gm-2): 0.6 1.0 1.5 2.0
Patients (n) 4 5 7 8
Weeks treatment 22 13 25 45
Adverse effect
and WHO grade
Diarrhoea 0 22 11 32 34
1 0 2 2 6
2 0 0 1 2
3 0 0 0 1
4 0 0 0 2
Vomiting 0 22 13 29 35
1 0 0 3 3
2 0 0 1 4
3 0 0 2 2
4 0 0 0 1
Oral ulcers 0 22 13 35 37
1 0 0 0 7
2 0 0 0 1
3 0 0 0 0
4 0 0 0 0
Table III Toxicity for eight patients receiving 2 g m-2 5-FU
WHO toxicity grade
Symptom 0 1 2 3 4
Diarrhoea 4 1 0 1 2
Vomiting 5 1 0 1 1
Oral ulceration 4 3 0 1 0
Discussion
The present study suggests that higher doses of 5-FU might
be tolerated with this intra-hepatic arterial regimen compared
with similar intravenous schedules. For example, Petrelli et
al. (1987) reported a 27% incidence of life threatening diarr-
hoea when administering only 0.6gm2 week-' of 5-FU in-
travenously in combination with folinic acid 500mg-2
week-' over a 6 week course. Sobrero et al. (1989) employed
the same intravenous treatment plan and experienced 20%
grade 3/4 diarrhoea. Other reported side effects include
stomatitis, conjunctivitis, vomiting and myelosuppression
(Machover et al., 1986; Petrelli et al., 1987; Erlichman, 1988;
Poon et al., 1989; Sobrero et al., 1989).
In the present study the main adverse effects were vomiting
and diarrhoea. Although patient 7 experienced grade 3
vomiting with 1.5 g m2 this was subsequently prevented by
administering dexamethasone 8 mg intravenous bolus at the
commencement of treatment therefore she proceeded to the
2 gm-2 dose. There was no myelosuppression. Furthermore,
there was no evidence of local complications such as gastro-
duodenal ulceration which might be expected to complicate
regional therapy (Chuang et al., 1981). Cholecystectomy was
undertaken at the time of catheter insertion therefore remov-
ing the risk of treatment-related cholecystitis (Lafon et al.,
1985).
One patient suffered a leak from his catheter injection port.
We suspect that this may have resulted from the unsatisfac-
tory design of some Huber 'non-coring' needles creating a
'punched-out' lesion in the port membrane (Haindl & Muller,
1988).
Folinic acid was not given over the entire 24 h 5-FU
infusion. In vitro studies have suggested that a minimum
extracellular L-folate concentration of 10Ismol 1-' is required
to maximise modulation of 5-FU thymidylate synthase
inhibition (Evans et al., 1981). A 2 h intravenous infusion of
200 mg m-2 would be expected to provide such a satisfactory
plasma folinic acid concentration (Anderson et al., 1991).
However, 24h intravenous infusions of 500mgm-2 folinic
acid fail to provide adequate plasma concentrations of folinicINTRA-HEPATIC ARTERIAL 5-FU 915
acid (Rustum, 1989). Furthermore, there is no available tox-
icity data for higher doses of 24 h folinic acid infusions. We
therefore elected to deliver a loading dose of folinic acid
during the first 2 h of the 5-FU infusion with a further dose
during the last 2 h of the 5-FU infusion when peak intracel-
lular 5-FU levels would be present.
Dose limiting toxicity in the present study was encountered
at 2 g m-2 5-FU. The recommended schedule of 5-FU is
therefore 1.5 g m-2 week-' as a 24 h intra-hepatic arterial
infusion with intravenous folinic acid 400 mg m2; 200 mg-
m-2 infused over the first 2 h of the 5-FU infusion and the
remaining 200 mg m-2 infused over the final 2 h of the 5-FU
infusion. This novel therapeutic option for patients with
colorectal liver metastases combines the pharmacokinetic
advantages of regional 5-FU with the efficacy enhancement
provided by folinic acid. We are currently undertaking phar-
macokinetic and phase II studies using this regimen.
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